Discover 238 paid clinical trials in Sioux Falls, South Dakota. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 238
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
for
Macular Edema Secondary to Inflammation
Location: Sioux Falls SD, Saint Louis Park MN, Wausau WI,
Sponsor: Kodiak Sciences Inc
Sex: All
Age: 18+
Code: NCT06996080
Phase 3, Recruiting
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
for
Obesity or Overweight, Type 2 Diabetes Mellitus
Location: Sioux Falls SD, Kansas City MO, Springfield IL,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT07351058
Phase 3, Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
for
Non-small Cell Lung Cancer
Location: Sioux Falls SD, Lincoln NE, Rochester MN, Waterloo IA,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06692738
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
for
Locally Advanced Head and Neck Squamous Cell Carcinoma
Location: Sioux Falls SD, Minneapolis MN, Des Moines IA, Niles IL,
Sponsor: AstraZeneca
Sex: All
Age: 18 - 70+
Code: NCT06129864
Phase 3, Recruiting
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
for
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma,
Location: Sioux Falls SD, Saint Louis Park MN, Minneapolis MN,
Sponsor: QuantumLeap Healthcare Collaborative
Sex: All
Age: 18+
Code: NCT01042379
Phase 2, Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
for
Biliary Tract Cancer
Location: Sioux Falls SD, Pierre SD, Rochester MN, Chicago IL,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT07221253
Phase 3, Recruiting
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
for
Asthma
Location: Sioux Falls SD, Omaha NE, Lincoln NE, Kansas City KS,
Sponsor: AstraZeneca
Sex: All
Age: 12 - 17
Code: NCT06307665
Phase 3, Recruiting
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
for
Endometrial Cancer, Malignant Solid Tumour
Location: Sioux Falls SD, Minneapolis MN, Peoria IL, Waukesha WI,
Sponsor: AstraZeneca
Sex: Female
Age: 18+
Code: NCT07044336
Phase 3, Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
for
Non-Small Cell Lung Cancer
Location: Sioux Falls SD, Omaha NE, Grand Island NE,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06357533
Phase 3, Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
for
Non-squamous Non-small Cell Lung Cancer
Location: Sioux Falls SD, Pierre SD, Lincoln NE, Saint Paul MN,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06627647
Phase 3, Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
for
COPD (Chronic Obstructive Pulmonary Disease)
Location: Sioux Falls SD, Sioux City IA, Fremont NE,
Sponsor: AstraZeneca
Sex: All
Age: 40 - 70+
Code: NCT06283966
Phase 3, Recruiting
Improving Neurodevelopmental ouTcomes After Prenatal Cannabinoid in uTero Exposure